CVRX241115C12500
- 0.60
- +0.07+13.21%
CVRx Inc Newsroom
Cantor Fitzgerald Maintains CVRx Inc(CVRX.US) With Buy Rating, Maintains Target Price $14
Lake Street Maintains CVRx Inc(CVRX.US) With Buy Rating, Maintains Target Price $12
CCORF Maintains CVRx Inc(CVRX.US) With Buy Rating, Maintains Target Price $15
CVRx Announces New CPT Category I Codes for Barostim
CVRx to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call on October 29, 2024
Craig-Hallum Maintains CVRx Inc(CVRX.US) With Buy Rating
Express News | CVRx: Borrows $20 Mln Under Final Tranche of Term Loan With Innovatus
CVRx Announces New Publication Reinforcing the Long-term Quality of Life Benefits of Barostim
Cantor Fitzgerald Initiates Coverage On CVRx With Overweight Rating, Announces Price Target of $14
Cantor Fitzgerald Initiates CVRx Inc(CVRX.US) With Buy Rating, Announces Target Price $14
Cantor Fitzgerald analyst Ross Osborn initiates coverage on $CVRx Inc(CVRX.US)$ with a buy rating, and sets the target price at $14.According to TipRanks data, the analyst has a success rate of 21.5%
Express News | CVRx Announces Appointment of Two New Board Members
CCORF Maintains CVRx Inc(CVRX.US) With Buy Rating, Maintains Target Price $15
CCORF analyst William Plovanic maintains $CVRx Inc(CVRX.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate of 41.7% and a total
CVRx Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
CVRx Price Target Maintained With a $12.00/Share by Lake Street
Lake Street Reiterates Buy on CVRx, Maintains $12 Price Target
CVRx Analyst Ratings
Lake Street Remains a Buy on CVRx (CVRX)
CVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Insider Buys Additional US$251k In CVRx Stock
Analysts Offer Insights on Healthcare Companies: CVRx (CVRX), Adaptive Biotechnologies (ADPT) and Rezolute (RZLT)